Cargando…
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study
BACKGROUND: Very few cancer patients were enrolled in coronavirus disease-2019 vaccine studies. In order to address this gap of knowledge, real-world studies are mandatory. The aim of this study was to assess both humoral and cellular response after a messenger RNA vaccination schedule. PATIENTS AND...
Autores principales: | Lasagna, A., Agustoni, F., Percivalle, E., Borgetto, S., Paulet, A., Comolli, G., Sarasini, A., Bergami, F., Sammartino, J.C., Ferrari, A., Zavaglio, F., Arena, F., Lilleri, D., Secondino, S., Falzoni, M., Schiavo, R., Klersy, C., Lo Cascio, G., Cavanna, L., Baldanti, F., Pedrazzoli, P., Cassaniti, I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8407964/ https://www.ncbi.nlm.nih.gov/pubmed/34543863 http://dx.doi.org/10.1016/j.esmoop.2021.100272 |
Ejemplares similares
-
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up
por: Lasagna, A., et al.
Publicado: (2021) -
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern
por: Lasagna, A., et al.
Publicado: (2022) -
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study
por: Lasagna, A., et al.
Publicado: (2022) -
Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment
por: Lasagna, A., et al.
Publicado: (2022) -
Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up
por: Lasagna, Angioletta, et al.
Publicado: (2023)